A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

NCT04566770 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo

Sponsor

CanSino Biologics Inc.

Collaborators

[object Object]
[object Object]